Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/IRCT20191026045244N2
IRCT20191026045244N2RecruitingPhase 3

Comparison of the effect and tolerability of Polycitra-k sachet with solution form on correction of urine metabolites and acidosis in treatment of pediatric with nephrolithiasis: Randomized clinical trial

Shahid Beheshti University of Medical Sciences0 sites50 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Phase 3
Status
Recruiting
Enrollment
50
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
no limit to no limit (—)
Sex
All

Inclusion Criteria

  • •Children and adolescents between 1 and 16 years of old with kidney stone
  • •-On ultrasound, kidney stones are larger than or equal to 5 mm
  • •-Without any history of recent urinary tract infection
  • •-Have normal kidney function
  • •-Without urinary tract anomalies

Exclusion Criteria

  • •-A child who needs urological intervention during the project.
  • •-A child who stops taking medication due to illness such as diarrhea, etc.
  • •-Any patient who does not want to continue the project.

Investigators

Similar Trials

Completed
Not Applicable
To find out effect and safety of polyethylene glycol and sodium hyaluronate in patient with dry eye disease
CTRI/2023/02/049510Pt BD Sharma PGIMS Rohtak50
Completed
Not Applicable
Comparative study of tolerability and efficacy of haloperidol versus olanzapine in schizophrenia
CTRI/2015/02/005575Government Medical College and Hospital40
Completed
Not Applicable
Efficacy and tolerability of imipramine, sertraline and des-venlafaxine in major depressio
CTRI/2015/05/005735Department of Psychiatry134
Active, not recruiting
Not Applicable
Comparative study of the efficacy and tolerance of intravenously administered azithromycin (1.5 g) given either as a single dose or over a 3 day period in patients with community-acquired pneumoniacommunity aquired pneumonia
EUCTR2005-000105-65-ATMedical University of Vienna, Department of Internal Med. I, Division of Infectious Diseases300
Active, not recruiting
Phase 1
Imiquimod versus PDT for actinic keratoses in in organ transplant recipients
EUCTR2012-000263-24-ATMedizinische Universität Wien, Univ. Klinik f. Dermatologie30